more

NuVasive, Inc. (NUVA)

(Delayed Data from NSDQ)

$62.96 USD

+0.74 (1.19%)

Updated May 3, 2019 04:00 PM ET

After-Market: $62.96 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Industry: NA

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Analysts Estimate NuVasive (NUVA) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research Published on April 29,2020

NuVasive (NUVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NUVAPositive Net Change

NuVasive (NUVA) Posts Q1 Preliminary Results, Withdraws View

by Zacks Equity Research Published on April 16,2020

A decline in elective surgical procedures due to coronavirus outbreak weighs on NuVasive's (NUVA) preliminary revenue results for first-quarter 2020.

medical

Here's Why You Should Hold on to NuVasive (NUVA) Stocks Now

by Zacks Equity Research Published on March 23,2020

Investors continue to be optimistic about NuVasive (NUVA) on its strong segmental and international results in the fourth quarter of 2019.

medical

Allscripts' Veradigm Business Line Unveils New Solution

by Zacks Equity Research Published on March 09,2020

Allscripts' (MDRX) Veradigm business line introduces new solution that will drive growing medication adherence and improve patient care.

medical

NuVasive (NUVA) Earnings and Revenues Beat Estimates in Q4

by Zacks Equity Research Published on February 21,2020

NuVasive's (NUVA) Biologics business returns to growth in the fourth quarter of 2019.

What's in Store for IDEXX Laboratories' (IDXX) Q4 Earnings?

by Zacks Equity Research Published on January 24,2020

IDEXX's (IDXX) is likely to report strong earnings for Q4, courtesy of a global surge in CAG Diagnostic revenues.

medical

What's in Store for Align Technology's (ALGN) Q4 Earnings?

by Zacks Equity Research Published on January 23,2020

Align Technology (ALGN) is expected to have gained from continued adoption of Invisalign system in Q4.

medical

Can NuVasive (NUVA) Keep the Earnings Surprise Streak Alive?

by Zacks Equity Research Published on January 20,2020

NuVasive (NUVA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

NUVAPositive Net Change

Can Abbott (ABT) Q4 Earnings Ride on Growth in All Lines?

by Zacks Equity Research Published on January 20,2020

Abbott's (ABT) imminent quarterly results are expected to reflect a solid performance by the Established Pharmaceuticals Division (EPD) business alike the last reported quarter.

NuVasive (NUVA) Stock Dips Despite Strong Preliminary Q4 Show

by Zacks Equity Research Published on January 16,2020

NuVasive's (NUVA) revenue growth will likely beat expectations for both the fourth quarter and 2019.

medical

Can Focus on High-Growth Area Up OrganiGram (OGI) Q1 Earnings?

by Zacks Equity Research Published on January 14,2020

OrganiGram (OGI) is expected to have benefited from its firm focus on building brand equity and ongoing product innovation in the fiscal first quarter.

Can Focus on High-Growth Area Up OrganiGram (OGI) Q1 Earnings?

by Zacks Equity Research Published on January 14,2020

OrganiGram (OGI) is expected to have benefited from its firm focus on building brand equity and ongoing product innovation in the fiscal first quarter.

Can New Strategic Efforts Aid Apharia's (APHA) Q2 Earnings?

by Zacks Equity Research Published on January 13,2020

Apharia (APHA) is successfully running its global cannabis business with more than 1,200 team members globally.

medical

Can Cannabis Therapy Drive Aphria's (APHA) Q2 Earnings?

by Zacks Equity Research Published on January 13,2020

Aphria (APHA) expects to deliver strong second-quarter fiscal 2020 results banking on solid performance of its cannabis therapy business.

Bio-Rad Gains on New Product Portfolio Despite Currency Woes

by Zacks Equity Research Published on December 30,2019

Bio-Rad's (BIO) new product uptake in the United States is appreciative with the recent 510(k) clearance of the IH-Reader 24.

medical

Here's Why You Should Add NuVasive Stock to Your Portfolio

by Zacks Equity Research Published on December 30,2019

Investors continue to be optimistic about NuVasive (NUVA) on its stellar segmental performance in Q3.

medical

Syneos Health (SYNH) Hits a 52-Week High: What's Driving It?

by Zacks Equity Research Published on December 30,2019

Syneos Health (SYNH) gains from several positive developments.

medical

Edwards (EW) Rides on Innovation Despite Regulatory Issues

by Zacks Equity Research Published on December 27,2019

Edwards Lifesciences' (EW) HemoSphere all-in-one monitoring platform is gaining momentum on the back of a strong rollout that sees a full-market launch.